Ross Muken
Stock Analyst at Evercore ISI Group
(1.94)
# 2,037
Out of 5,090 analysts
47
Total ratings
55.56%
Success rate
0.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Outperform | $190 → $200 | $184.31 | +8.51% | 9 | Oct 3, 2025 | |
| HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $73.62 | -4.92% | 10 | Aug 6, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $185.80 | +29.17% | 9 | Jul 25, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $145.49 | -10.65% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $47.01 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $198.83 | -66.30% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $128.96 | +93.86% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $572.77 | -61.59% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $11.70 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Oct 3, 2025
Maintains: Outperform
Price Target: $190 → $200
Current: $184.31
Upside: +8.51%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $73.62
Upside: -4.92%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $185.80
Upside: +29.17%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $145.49
Upside: -10.65%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $47.01
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $198.83
Upside: -66.30%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $128.96
Upside: +93.86%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $572.77
Upside: -61.59%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $11.70
Upside: -